Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Lectin with Sialic Acid Specificity Blocks Melanoma Metastasis in Mouse Model

By LabMedica International staff writers
Posted on 06 Aug 2012
A lectin isolated from the seeds of the Maackia amurensis tree blocks the migration of melanoma cells both in culture dishes and in a mouse skin-cancer model.

Maackia amurensis has been used as a medicinal plant for several centuries to treat ailments including cancer in parts of Asia. More...
Modern studies point to a lectin, MASL, with specificity for alpha-2,3-sialic acid residues as being the medically active component. Lectins are plant proteins or glycoproteins that bind with high specificity to sugar moieties such as those found on cell membrane surface glycoproteins.

Investigators at the University of Medicine and Dentistry of New Jersey (Newark, USA) treated melanoma cell cultures with MASL and treated mice with skin cancer with oral doses of MASL over a period of three weeks. The combination of MASL and melanoma was selected for study because prior research had shown that motility of melanoma cells was regulated by the mucin-receptor protein podoplanin (PDPN). PDPN is activated by endogenous ligands to induce tumor cell motility and metastasis. The extracellular domain of PDPN is highly O-glycosylated with alpha-2,3-sialic acid linked to galactose.

Results reported in the July 23, 2012, online edition of the journal PLoS ONE revealed that MASL inhibited melanoma cell growth, migration, and tumorigenesis under the controlled conditions of cell culture. What was more surprising was that the lectin effectively blocked melanoma metastasis in the skin after passing through the digestive tracts of the mice. Of critical importance to future drug development was the finding that MASL caused no notable toxic effects on organ morphology or animal behavior over the three-week period of treatment.

“Cells, even when they are cancerous, tend to stay put,” said senior author Dr. Gary Goldberg, professor of molecular biology at the University of Medicine and Dentistry of New Jersey. “PDPN allows tumor cells to break out of their microenvironment, invade new areas, and metastasize. Our laboratory research shows that MASL not only significantly reduces cell migration it also inhibits cancer cell growth. The absence of any noticeable side effects is not surprising. For centuries, MASL has been taken as a component in medicinal plant extracts used to treat a variety of ailments including cancer. According to standard traditional protocols, these preparations contain very high doses of MASL, yet we cannot find any reports of toxicity from its use.”

Related Links:
University of Medicine and Dentistry of New Jersey




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.